Phoenix Molecular Imaging Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01304485
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Medical Director, Phoenix Molecular Imaging

Active Ingredients

Drugs in Phase 3 Trials (1)

sodium acetate (2 trials)

Drugs in Phase 2 Trials (1)

c11-sodium acetate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma (Phase 2)

Disease Progression (Phase 3)

Glioma (Phase 3)

Necrosis (Phase 3)

Neoplasm Metastasis (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2